title: The trends of one-week first-line and second-line eradication therapy for Helicobacter pylori infection in Korea.
abstract: OBJECTIVE
  Increasing levels of bacterial antibiotic resistance raise the need to assess the eradication efficiency of Helicobacter pylori. The aim of this study was to evaluate 7-year changes in efficacy of one-week first line and second line therapies in Helicobacter pylori eradication rates in Korea.
  
  
  METHODS
  From 2001 to 2007, 4198 Helicobacter pylori-positive patients received first-line therapy (proton pump inhibitor, amoxicillin 1,000 mg b.i.d., and clarithromycin 500 mg b.i.d.). Four hundred ninety patients received second-line therapy (proton pump inhibitor twelve hourly, metronidazole 500 mg t.i.d., tetracycline 500 mg q.i.d., and bismuth 300 mg q.i.d.). A 13C-urea breath test was used to determine the eradication rate.
  
  
  RESULTS
  The eradication rates of first-line therapy were 81.3%, 83.7%, 80.1%, 80.7%, 82.0%, 75.9%, and 77.5% from 2001 to 2007, with a decreasing trend (p < 0.01). The eradication rate of second-line therapy was 77.3%, 86.2%, 95.6%, 95.9%, 89.6%, 83.2%, and 86.4% from 2001 to 2007 without decreasing trend (p = 0.26).
  
  
  CONCLUSIONS
  The eradication rate of first-line therapy has decreased in the last 7 years while that of second-line therapy has remained the same. A new strategy is required to improve the first-line therapy for Helicobacter pylori eradication in Korea.
authors.affiliation: Department of Internal Medicine, Gachon University, Gil Medical Center, Incheon.
authors.forename: Jun-Won
authors.initials: JW
authors.lastname: Chung
authors.forename: Gin Hyug
authors.initials: GH
authors.lastname: Lee
authors.forename: Jeung Hye
authors.initials: JH
authors.lastname: Han
authors.forename: Jin-Yong
authors.initials: JY
authors.lastname: Jeong
authors.forename: Kwi-Sook
authors.initials: KS
authors.lastname: Choi
authors.forename: Do Hoon
authors.initials: DH
authors.lastname: Kim
authors.forename: Kee Wook
authors.initials: KW
authors.lastname: Jung
authors.forename: Kee Don
authors.initials: KD
authors.lastname: Choi
authors.forename: Ho June
authors.initials: HJ
authors.lastname: Song
authors.forename: Hwoon-Yong
authors.initials: HY
authors.lastname: Jung
authors.forename: Jin-Ho
authors.initials: JH
authors.lastname: Kim
mesh_terms: D000658:Amoxicillin / Q000627:therapeutic use*; D001729:Bismuth / Q000627:therapeutic use*; D001944:Breath Tests; D017291:Clarithromycin / Q000627:therapeutic use*; D024881:Drug Resistance, Bacterial; D004359:Drug Therapy, Combination; D016481:Helicobacter Infections / Q000175:diagnosis / Q000188:drug therapy* / Q000453:epidemiology; D016480:Helicobacter pylori; D006801:Humans; D008795:Metronidazole / Q000627:therapeutic use*; D010818:Practice Patterns, Physicians' / Q000639:trends*; D054328:Proton Pump Inhibitors / Q000627:therapeutic use*; D056910:Republic of Korea / Q000453:epidemiology; D013752:Tetracycline / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D054328:Proton Pump Inhibitors; D008795:Metronidazole; D000658:Amoxicillin; D013752:Tetracycline; D017291:Clarithromycin; D001729:Bismuth